NCT01979276View on ClinicalTrials.gov

Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Multiple Myeloma
Interventions
DRUG

Romidepsin

Romidepsin intravenously on days 1 and 15 of a 28-day cycle

DRUG

pomalidomide

Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle

DRUG

Dexamethasone

Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle

Trial Locations (1)

10065

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT01979276 - Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma | Biotech Hunter | Biotech Hunter